Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RET IRD 02 extension study of repeated oral QLT091001 in RPE65/LRAT-related LCA or RP
NL-OMON39289Phase 2Active, not recruiting
- Sponsor
- QLT Inc.
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zuretinol in Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP), sponsored by QLT Inc. Primary endpoints: Assessment of Vision and Assessment of Safety. Started Oct 2012; status: active, not recruiting.
02
Drugs
zuretinol
03
Conditions
Leber congenital amaurosis (LCA)retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NL-OMON39289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39289.